@article{CCO22268,
author = {Tatiana V. Gorodnova and Anna P. Sokolenko and Ekatherina Kuligina and Igor V. Berlev and Evgeny N. Imyanitov},
title = {Principles of clinical management of ovarian cancer},
journal = {Chinese Clinical Oncology},
volume = {7},
number = {6},
year = {2018},
keywords = {},
abstract = {Epithelial ovarian cancer (EOC) is a common malignant disease, which remains asymptomatic for a prolonged period of time and is usually diagnosed at advanced stages. Cytoreductive surgery is a backbone of EOC treatment. Wherever possible, EOC patients are subjected to primary debulking surgery (PDS) with the aim to remove all visible tumor lumps. Some patients cannot undergo PDS due to extensive disease spread and/or high risk of perioperative morbidity, therefore they are subjected to neoadjuvant chemotherapy (NACT) before the surgery. Therapy given before surgery or as adjuvant treatment usually consists of combination of carboplatin and paclitaxel. Gemcitabine, topotecan, pegylated liposomal doxorubicin and poly ADP ribose polymerase inhibitors (PARPi) are commonly used for the management of EOC relapses. Consideration of BRCA1/2 germ-line and somatic status is getting increasingly important for the proper treatment planning.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/22268}
}